Prospective superficial EPR in-vivo dosimetry study during hypofractionated radiotherapy of breast cancer patients treated with helical tomotherapy

dc.contributor.authorHöfel, Sebastian
dc.contributor.authorGandalini, Matteo
dc.contributor.authorFix, Michael K.
dc.contributor.authorDrescher, Malte
dc.contributor.authorZwicker, Felix
dc.date.accessioned2021-11-03T13:23:46Z
dc.date.available2021-11-03T13:23:46Z
dc.date.issued2021-10-30eng
dc.description.abstractBackground
In-vivo dosimetry (IVD) is a patient specific measure of quality control and safety during radiotherapy. With regard to current reporting thresholds for significant occurrences in radiotherapy defined by German regulatory authorities, the present study examines the clinical feasibility of superficial electron paramagnetic resonance (EPR) IVD of cumulative total doses applied to breast cancer patients treated with helical intensity-modulated radiotherapy (tomotherapy).

Methods
In total, 10 female patients with left- or right-sided breast cancer were enrolled in this prospective IVD study. Each patient received a hypofractionated whole breast irradiation. A total median dose of 42.4 Gy in 16 fractions (5 fractions per week) was prescribed to the planning target volume. The treatments were completely delivered using helical tomotherapy and daily image guidance via megavoltage CT (MVCT). For each patient, three EPR dosimeters were prepared and placed at distinct locations on the patient’s skin during the delivery of all fractions. Two dosimeters were placed next to the ipsilateral and contralateral mammilla and one dosimeter was placed ventrally to the thyroid (out-of-primary-beam). The total doses delivered to the dosimeters were readout after all fractions had been administered. The measured total dose values were compared to the planned dose values derived from the treatment planning system (TPS). Daily positional variations (displacement vectors) of the ipsilateral mammilla and of the respective dosimeter were analyzed with respect to the planned positions using the daily registered MVCT image.

Results
Averaged over all patients, the mean absolute dose differences between measured and planned total dose values (± standard deviation (SD)) were: 0.49 ± 0.85 Gy for the ipsilateral dosimeter, 0.17 ± 0.49 Gy for the contralateral dosimeter and -0.12 ± 0.30 Gy for the thyroid dosimeter. The mean lengths of the ipsilateral displacement vectors (± SD) averaged over all patients and fractions were: 10 ± 7 mm for the dosimeter and 8 ± 4 mm for the mammilla.

Conclusion
Superficial EPR IVD is suitable as additional safeguard for dose delivery during helical tomotherapy of breast cancer. Despite positional uncertainties in clinical routine, the observed dose deviations at the ipsilateral breast were on average small compared to national reporting thresholds for total dose deviations (i.e. 10%/4 Gy). EPR IVD may allow for the detection of critical dose errors during whole breast irradiations.
eng
dc.description.versionpublishedeng
dc.identifier.doi10.1186/s13014-021-01938-8eng
dc.identifier.pmid34717680eng
dc.identifier.ppn1776041925
dc.identifier.urihttps://kops.uni-konstanz.de/handle/123456789/55431
dc.language.isoengeng
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectIn vivo, EPR dosimetry, Lithium formate, Alanine, Breast cancer, Radiotherapy, IMRT, Tomotherapy, Hypofractionatedeng
dc.subject.ddc540eng
dc.titleProspective superficial EPR in-vivo dosimetry study during hypofractionated radiotherapy of breast cancer patients treated with helical tomotherapyeng
dc.typeJOURNAL_ARTICLEeng
dspace.entity.typePublication
kops.citation.bibtex
@article{Hofel2021-10-30Prosp-55431,
  year={2021},
  doi={10.1186/s13014-021-01938-8},
  title={Prospective superficial EPR in-vivo dosimetry study during hypofractionated radiotherapy of breast cancer patients treated with helical tomotherapy},
  number={1},
  volume={16},
  journal={Radiation Oncology},
  author={Höfel, Sebastian and Gandalini, Matteo and Fix, Michael K. and Drescher, Malte and Zwicker, Felix},
  note={Article Number: 209}
}
kops.citation.iso690HÖFEL, Sebastian, Matteo GANDALINI, Michael K. FIX, Malte DRESCHER, Felix ZWICKER, 2021. Prospective superficial EPR in-vivo dosimetry study during hypofractionated radiotherapy of breast cancer patients treated with helical tomotherapy. In: Radiation Oncology. BioMed Central. 2021, 16(1), 209. eISSN 1748-717X. Available under: doi: 10.1186/s13014-021-01938-8deu
kops.citation.iso690HÖFEL, Sebastian, Matteo GANDALINI, Michael K. FIX, Malte DRESCHER, Felix ZWICKER, 2021. Prospective superficial EPR in-vivo dosimetry study during hypofractionated radiotherapy of breast cancer patients treated with helical tomotherapy. In: Radiation Oncology. BioMed Central. 2021, 16(1), 209. eISSN 1748-717X. Available under: doi: 10.1186/s13014-021-01938-8eng
kops.citation.rdf
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/55431">
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-11-03T13:23:46Z</dcterms:available>
    <dcterms:issued>2021-10-30</dcterms:issued>
    <dc:creator>Fix, Michael K.</dc:creator>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dc:contributor>Fix, Michael K.</dc:contributor>
    <dc:language>eng</dc:language>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/55431/1/Hoefel_2-1tl3r6znst36o3.pdf"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-11-03T13:23:46Z</dc:date>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/55431/1/Hoefel_2-1tl3r6znst36o3.pdf"/>
    <dc:creator>Zwicker, Felix</dc:creator>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/41"/>
    <dc:contributor>Gandalini, Matteo</dc:contributor>
    <dc:contributor>Drescher, Malte</dc:contributor>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Gandalini, Matteo</dc:creator>
    <dcterms:title>Prospective superficial EPR in-vivo dosimetry study during hypofractionated radiotherapy of breast cancer patients treated with helical tomotherapy</dcterms:title>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/41"/>
    <dc:contributor>Höfel, Sebastian</dc:contributor>
    <dc:contributor>Zwicker, Felix</dc:contributor>
    <dcterms:abstract xml:lang="eng">Background&lt;br /&gt;In-vivo dosimetry (IVD) is a patient specific measure of quality control and safety during radiotherapy. With regard to current reporting thresholds for significant occurrences in radiotherapy defined by German regulatory authorities, the present study examines the clinical feasibility of superficial electron paramagnetic resonance (EPR) IVD of cumulative total doses applied to breast cancer patients treated with helical intensity-modulated radiotherapy (tomotherapy).&lt;br /&gt;&lt;br /&gt;Methods&lt;br /&gt;In total, 10 female patients with left- or right-sided breast cancer were enrolled in this prospective IVD study. Each patient received a hypofractionated whole breast irradiation. A total median dose of 42.4 Gy in 16 fractions (5 fractions per week) was prescribed to the planning target volume. The treatments were completely delivered using helical tomotherapy and daily image guidance via megavoltage CT (MVCT). For each patient, three EPR dosimeters were prepared and placed at distinct locations on the patient’s skin during the delivery of all fractions. Two dosimeters were placed next to the ipsilateral and contralateral mammilla and one dosimeter was placed ventrally to the thyroid (out-of-primary-beam). The total doses delivered to the dosimeters were readout after all fractions had been administered. The measured total dose values were compared to the planned dose values derived from the treatment planning system (TPS). Daily positional variations (displacement vectors) of the ipsilateral mammilla and of the respective dosimeter were analyzed with respect to the planned positions using the daily registered MVCT image.&lt;br /&gt;&lt;br /&gt;Results&lt;br /&gt;Averaged over all patients, the mean absolute dose differences between measured and planned total dose values (± standard deviation (SD)) were: 0.49 ± 0.85 Gy for the ipsilateral dosimeter, 0.17 ± 0.49 Gy for the contralateral dosimeter and -0.12 ± 0.30 Gy for the thyroid dosimeter. The mean lengths of the ipsilateral displacement vectors (± SD) averaged over all patients and fractions were: 10 ± 7 mm for the dosimeter and 8 ± 4 mm for the mammilla.&lt;br /&gt;&lt;br /&gt;Conclusion&lt;br /&gt;Superficial EPR IVD is suitable as additional safeguard for dose delivery during helical tomotherapy of breast cancer. Despite positional uncertainties in clinical routine, the observed dose deviations at the ipsilateral breast were on average small compared to national reporting thresholds for total dose deviations (i.e. 10%/4 Gy). EPR IVD may allow for the detection of critical dose errors during whole breast irradiations.</dcterms:abstract>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/55431"/>
    <dc:creator>Drescher, Malte</dc:creator>
    <dc:creator>Höfel, Sebastian</dc:creator>
  </rdf:Description>
</rdf:RDF>
kops.description.openAccessopenaccessgoldeng
kops.flag.isPeerReviewedtrueeng
kops.flag.knbibliographytrue
kops.identifier.nbnurn:nbn:de:bsz:352-2-1tl3r6znst36o3
kops.sourcefieldRadiation Oncology. BioMed Central. 2021, <b>16</b>(1), 209. eISSN 1748-717X. Available under: doi: 10.1186/s13014-021-01938-8deu
kops.sourcefield.plainRadiation Oncology. BioMed Central. 2021, 16(1), 209. eISSN 1748-717X. Available under: doi: 10.1186/s13014-021-01938-8deu
kops.sourcefield.plainRadiation Oncology. BioMed Central. 2021, 16(1), 209. eISSN 1748-717X. Available under: doi: 10.1186/s13014-021-01938-8eng
relation.isAuthorOfPublicationf0b3f22e-33c7-4570-8df1-0c8f347b56c1
relation.isAuthorOfPublication50c78ea9-293f-4d20-a06a-32f84ce06269
relation.isAuthorOfPublication.latestForDiscoveryf0b3f22e-33c7-4570-8df1-0c8f347b56c1
source.bibliographicInfo.articleNumber209eng
source.bibliographicInfo.issue1eng
source.bibliographicInfo.volume16eng
source.identifier.eissn1748-717Xeng
source.periodicalTitleRadiation Oncologyeng
source.publisherBioMed Centraleng

Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
Hoefel_2-1tl3r6znst36o3.pdf
Größe:
1.46 MB
Format:
Adobe Portable Document Format
Beschreibung:
Hoefel_2-1tl3r6znst36o3.pdf
Hoefel_2-1tl3r6znst36o3.pdfGröße: 1.46 MBDownloads: 190

Lizenzbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
license.txt
Größe:
3.96 KB
Format:
Item-specific license agreed upon to submission
Beschreibung:
license.txt
license.txtGröße: 3.96 KBDownloads: 0